Ann: Imugene AGM Presentation, page-132

Guys, this is not financial advice or investment advice. IMO/DYOR.

1. Follow Upcoming Trial Results and Expansion Phases

• Keep track of interim results from the ongoing Phase 1b trials and any early Phase 2 trials, as these will provide a clearer picture of efficacy and safety.
• Look for updates on the expansion of the azer-cel trial to additional blood cancers, as well as the development of onCARlytics in combination trials for solid tumors. Positive interim results in these areas could significantly increase market interest.

2. Watch for Partnerships and Licensing Deals

• Since Imugene’s commercialization strategy leans towards partnerships, watch for collaborations with major pharmaceutical companies. A partnership or licensing agreement, especially with an upfront payment, would validate Imugene’s technology and provide additional capital for continued development.
• Partnering with companies experienced in large-scale commercialization and regulatory navigation could expedite the path to market.

3. Monitor Regulatory Milestones

• Pay close attention to any Fast Track or Breakthrough Therapy Designations that Imugene may pursue for its other therapies, as these can shorten the regulatory timeline. Any meeting updates or discussions with the FDA will offer insight into the likely timeline for Imugene's lead therapies.

4. Evaluate Funding and Cash Position

• Given Imugene’s ambitious R&D pipeline, it’s essential to assess their cash reserves and any upcoming capital raises or grant funding. Adequate funding will ensure continued trial progression without significant dilution.
• Look for funding announcements and carefully review terms of any equity offerings or debt financing, as well as Imugene’s burn rate and anticipated cash runway.

5.Stay Updated on Competitive Developments

• As CAR T-cell and oncolytic virus therapies are competitive fields, tracking advancements by other biotech companies is key. This can help assess Imugene’s relative position and adaptability within the immunotherapy space, particularly regarding any FDA approvals of similar therapies by competitors.

6. Assess Strategic Milestones for Valuation Impact

• Monitor Imugene’s pathway to potential Phase 3 trials or commercialization milestones, as these are key valuation drivers. For instance, successful Phase 1b results with evidence of sustained efficacy and safety could lead to a valuation reassessment if Imugene chooses to license or independently pursue a Phase 3 trial.
• Keep an eye on the timing and specifics of any pivotal data releases, as these could significantly influence stock performance.

7. Consider Long-Term Commercialization Potential

• Assess Imugene’s long-term positioning for market adoption, particularly regarding azer-cel as a potentially off-the-shelf CAR T-cell therapy. If they make successful progress in solid tumor targeting with onCARlytics or VAXINIA, these could represent game-changing treatments, making Imugene an attractive long-term investment.
• Evaluate the likelihood of reimbursement strategies and target markets, as well as any proactive engagement Imugene has with healthcare payers or insurers, which would be important for future revenue generation.

8. Assess Broader Market Conditions in Biotech

• Given that the biotech sector is often sensitive to regulatory shifts and broader economic factors, evaluate Imugene within the context of current trends in biotech funding, FDA approval rates, and investor sentiment.
• Also, if biotech funding becomes constrained, companies like Imugene may face higher hurdles in securing capital, which could delay projects or push them toward strategic partnerships sooner.

By closely tracking these milestones and maintaining a long-term perspective on Imugene’s innovative but still developmental technologies, you can make informed decisions based on tangible progress and strategic advancements.